fidaxomicin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Inflammatory Bowel Disease (IBD)

Conditions

Inflammatory Bowel Disease (IBD), Clostridium Difficile Infection (CDI)

Trial Timeline

Aug 13, 2015 → Oct 24, 2016

NCT ID

NCT02437591

About fidaxomicin

fidaxomicin is a approved stage product being developed by Astellas Pharma for Inflammatory Bowel Disease (IBD). The current trial status is completed. This product is registered under clinical trial identifier NCT02437591. Target conditions include Inflammatory Bowel Disease (IBD), Clostridium Difficile Infection (CDI).

What happened to similar drugs?

9 of 20 similar drugs in Inflammatory Bowel Disease (IBD) were approved

Approved (9) Terminated (3) Active (11)

✅Infliximab + Infliximab + InfliximabCelltrionApproved

✅RisankizumabAbbVieApproved

✅Human Papillomavirus VaccineMerckApproved

✅BezlotoxumabMerckApproved

✅Celecoxib + Ibuprofen plus OmeprazolePfizerApproved

✅Alemtuzumab infusionSanofiApproved

✅IgPro10CSLApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02437591	Approved	Completed	Aug 13, 2015	Oct 24, 2016	Inflammatory Bowel Disease (IBD)

Competing Products

20 competing products in Inflammatory Bowel Disease (IBD)

See all competitors

Product	Company	Stage	Hype Score
Infliximab + Infliximab + Infliximab	Celltrion	Approved	50
CT-P13	Celltrion	Phase 3	36
Subcutaneous infliximab CT-P13 Remsima®SC	Celltrion	Pre-clinical	22
Infliximab subcutaneous + Immunosuppressive Agents	Celltrion	Phase 3	47
Eribulin + Adriamycin + Cyclophosphamide	Eisai	Phase 2	39
E6007 + E6007 + E6007 + E6007 + E6007 + E6007	Eisai	Phase 1	29
Placebo + MORF-057	Eli Lilly	Phase 2	42
Baricitinib + Baricitinib	Eli Lilly	Phase 2	35
LY3114062 SC + Placebo + LY3114062 IV	Eli Lilly	Phase 1	29
MORF-057 + Placebo	Eli Lilly	Phase 2	39
MORF-057	Eli Lilly	Phase 2	35
LY3009104	Eli Lilly	Phase 1	29
HRF2105 patch + Loxoprofen patch + placebo	Jiangsu Hengrui Medicine	Phase 2	31
Risankizumab	AbbVie	Approved	43
GC012F Injection infusion	AstraZeneca	Phase 1	36
AZD6793 + Placebo	AstraZeneca	Phase 1	29
Human Papillomavirus Vaccine	Merck	Approved	43
Pembrolizumab	Merck	Phase 2	31
Gardasil vaccine	Merck	Pre-clinical	26
Bezlotoxumab	Merck	Approved	35